Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

636 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E, Annunziata M, Stagno F, Tiribelli M, Binotto G, Bonifacio M, Fava C, Iurlo A, Bucelli C, Mansueto G, Gozzini A, Falzetti F, Montefusco E, Crisà E, Gugliotta G, Russo S, Cedrone M, RussoRossi A, Pregno P, Isidori A, Mauro E, Atelda R, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Galimberti S, Orlandi E, Calistri E, Bocchia M, Cavazzini F, Rege Cambrin G, Orofino N, Luciano L, Sgherza N, Rosti G, Latagliata R, Capodanno I. Crugnola M, et al. Among authors: isidori a. Ann Hematol. 2019 Oct;98(10):2329-2338. doi: 10.1007/s00277-019-03767-y. Epub 2019 Aug 7. Ann Hematol. 2019. PMID: 31392461 Clinical Trial.
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
Visani G, Breccia M, Gozzini A, Specchia G, Montefusco E, Morra E, Annunziata M, Camera A, Cavazzini F, Stagno F, Pregno P, Usala E, Santini V, Piccaluga PP, Isidori A. Visani G, et al. Among authors: isidori a. Am J Hematol. 2010 Dec;85(12):960-3. doi: 10.1002/ajh.21871. Am J Hematol. 2010. PMID: 21069865 Free article. No abstract available.
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia.
Latagliata R, Isidori A, Breccia M, Carmosino I, Vozella F, Volpicelli P, Finsinger P, Barulli S, Loglisci G, Santopietro M, Federico V, Diverio D, Nanni M, Mancini M, Visani G, Alimena G. Latagliata R, et al. Among authors: isidori a. Acta Haematol. 2013;129(2):126-34. doi: 10.1159/000343384. Epub 2012 Nov 28. Acta Haematol. 2013. PMID: 23207803 Free article.
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, Fava C, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege-Cambrin G, Luciano L, Alimena G. Latagliata R, et al. Among authors: isidori a. Drugs Aging. 2013 Aug;30(8):629-37. doi: 10.1007/s40266-013-0088-6. Drugs Aging. 2013. PMID: 23681399
Conditioning regimens in acute myeloid leukemia.
Visani G, Malagola M, Guiducci B, Lucesole M, Loscocco F, Gabucci E, Paolini S, Piccaluga PP, Isidori A. Visani G, et al. Among authors: isidori a. Expert Rev Hematol. 2014 Aug;7(4):465-79. doi: 10.1586/17474086.2014.939066. Expert Rev Hematol. 2014. PMID: 25025371 Review.
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, Trawinska MM, Annunziata M, Stagno F, Tiribelli M, Binotto G, Crisà E, Musto P, Gozzini A, Cavalli L, Montefusco E, Iurlo A, Russo S, Cedrone M, Rossi AR, Pregno P, Endri M, Spadea A, Molica M, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Cambrin GR, Isidori A, Sica S, Abruzzese E, Speccha G, Rosti G, Alimena G. Breccia M, et al. Among authors: isidori a. Leuk Res. 2014 Oct;38(10):1173-6. doi: 10.1016/j.leukres.2014.06.020. Epub 2014 Jul 7. Leuk Res. 2014. PMID: 25047978
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party. Castagnetti F, et al. Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19. Leukemia. 2015. PMID: 26088952 Clinical Trial.
Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.
Breccia M, Abruzzese E, Iurlo A, Gozzini A, Isidori A, Gangemi D, Pregno P, Alimena G. Breccia M, et al. Among authors: isidori a. Haematologica. 2016 Jun;101(6):e267-8. doi: 10.3324/haematol.2016.145623. Epub 2016 May 31. Haematologica. 2016. PMID: 27252515 Free PMC article. Clinical Trial. No abstract available.
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.
Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A. Iurlo A, et al. Among authors: isidori a. Oncotarget. 2016 Nov 29;7(48):80083-80090. doi: 10.18632/oncotarget.11657. Oncotarget. 2016. PMID: 27579540 Free PMC article.
636 results